Progressive improvement in wound healing with increased therapy in haemophilia B mice

Haemophilia

Volumn 19, Issue 6, 2013, Pages 926-932

  Monroe, D M ^a   Hoffman, M ^b   Roberts, H R ^a   Hedner, U ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Bleeding; Factor IX; Factor VIIa; Haemophilia; Mouse models; Wound healing

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; IRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; CONTROLLED STUDY; HEMATOMA; HEMOPHILIA B; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBSTITUTION THERAPY; WOUND HEALING;

BLEEDING; FACTOR IX; FACTOR VIIA; HAEMOPHILIA; MOUSE MODELS; WOUND HEALING;

ANIMALS; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; FACTOR IX; FACTOR VIIA; HEMATOMA; HEMOPHILIA B; IRON; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; WOUND HEALING;

EID: 84886641038     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12220     Document Type: Article

References (43)

1. Witte MB, Barbul A. General principles of wound healing. Surg Clin North Am 1997; 77: 509-28.
2. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341: 738-46.
3. Drew AF, Liu H, Davidson JM, Daugherty CC, Degen JL. Wound-healing defects in mice lacking fibrinogen. Blood 2001; 97: 3691-8.
4. Romer J, Bugge TH, Pyke C et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996; 2: 287-92.
5. Inbal A, Lubetsky A, Krapp T et al. Impaired wound healing in factor XIII deficient mice. Thromb Haemost 2005; 94: 432-7.
6. Bar-Shavit R, Kahn A, Fenton JW, Wilner GD. Chemotactic response of monocytes to thrombin. J Cell Biol 1983; 96: 282-5.
7. Dawes KE, Gray AJ, Laurent GJ. Thrombin stimulates fibroblast chemotaxis and replication. Eur J Cell Biol 1993; 61: 126-30.
8. Cox S, Cole M, Tawil B. Behavior of human dermal fibroblasts in three-dimensional fibrin clots: dependence on fibrinogen and thrombin concentration. Tissue Eng 2004; 10: 942-54.
9. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
10. Norfleet AM, Bergmann JS, Carney DH. Thrombin peptide, TP508, stimulates angiogenic responses in animal models of dermal wound healing, in chick chorioallantoic membranes, and in cultured human aortic and microvascular endothelial cells. Gen Pharmacol 2000; 35: 249-54.
11. Strukova SM, Dugina TN, Chistov IV et al. Immobilized thrombin receptor agonist peptide accelerates wound healing in mice. Clin Appl Thromb Hemost 2001; 7: 325-9.
12. Landis RC. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am 2007; 21: 103-13.
13. Sixma JJ, van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol 1984; 58: 741-53.
14. Monroe DM, Hoffman M. The clotting system - a major player in wound healing. Haemophilia 2012; 18(Suppl 5): 11-6.
15. Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM. Cutaneous wound healing is impaired in hemophilia B. Blood 2006; 108: 3053-60.
16. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2: 402-13.
17. Brummel-Ziedins KE, Whelihan MF, Gissel M, Mann KG, Rivard GE. Thrombin generation and bleeding in haemophilia A. Haemophilia 2009; 15: 1118-25.
18. Collet JP, Allali Y, Lesty C et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-73.
19. He S, Blombäck M, Bark N, Johnsson H, Wallén NH. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis. Thromb Haemost 2010; 103: 1076-84.
20. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21: 131-42.
21. McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost 2007; 5: 1577-83.
22. Nilsson IM, Ahlberg A, Björlin G. Clinical experience with a Swedish factor IX concentrate. Acta Med Scand 1971; 190: 257-66.
23. Rodriguez-Merchan EC. Surgical wound healing in bleeding disorders. Haemophilia 2012; 18: 487-90.
24. Wolff LJ, Lovrien EW. Management of fractures in hemophilia. Pediatrics 1982; 70: 431-6.
25. Rodriguez-Merchan EC. Bone fractures in the haemophilic patient. Haemophilia 2002; 8: 104-11.
26. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-6.
27. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Røjkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003; 102: 3615-20.
28. Gui T, Lin H-F, Jin D-Y et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002; 100: 153-8.
29. Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 2003; 1: 112-9.
30. Clark CA, Vatsyayan R, Hedner U, Esmon CT, Pendurthi UR, Rao LVM. Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa. J Thromb Haemost 2012; 10: 2383-91.
31. Cochran WG. Some Methods for Strengthening the Common χ2 Tests. Biometrics 1954; 10: 417-51.
32. Armitage P. Tests for Linear Trends in Proportions and Frequencies. Biometrics 1955; 11: 375-86.
33. Kung SH, Hagstrom JN, Cass D et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood 1998; 91: 784-90.
34. Petersen LC, Nørby PL, Branner S et al. Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study. Thromb Res 2005; 116: 75-85.
35. Pendurthi UR, Rao LVM. Factor VIIa/tissue factor-induced signaling: a link between clotting and disease. Vitam Horm 2002; 64: 323-55.
36. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 2003; 1: 1495-503.
37. Rao LVM, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 2005; 25: 47-56.
38. Gopalakrishnan R, Hedner U, Ghosh S et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2010; 8: 301-10.
39. Hjortoe GM, Petersen LC, Albrektsen T et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004; 103: 3029-37.
40. Pan-Petesch B, Laguna P, Mital A et al. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres. Haemophilia 2009; 15: 760-5.
41. Lisman T, Mosnier LO, Lambert T et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99: 175-9.
42. Hvas A-M, Sørensen HT, Norengaard L, Christiansen K, Ingerslev J, Sørensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007; 5: 2408-14.
43. Frank S, Kämpfer H, Wetzler C, Pfeilschifter J. Nitric oxide drives skin repair: novel functions of an established mediator. Kidney Int 2002; 61: 882-8.